Back to results
US 5,700,469 AGranted
HIV-1 core protein fragments
AssigneeMedical Research Council
InventorsAndre James McMichael, Douglas Fraser Nixon, Alain Robert Michael Townsend, Frances Margaret Gotch
Life of this patent
Estimating the term…
Abstract
The present invention provides peptidal fragments of human immunodeficiency virus (HIV) which interact specifically with a particular human leucocyte antigen (HLA) class I molecule to stimulate cytotoxic T lymphocyte immunity.
Claims21
A pharmaceutical composition, comprising:
- (A) a pharmaceutically acceptable carrier;
- and
- (B) a peptide selected from the group consisting of:
- (1) a peptide having the amino acid sequence NH.sub.2 -valine-glutamine-asparagine-alanine-asparagine-proline-aspartic acid-cysteine-lysine-threonine-isoleucine-leucine-lysine-alanine-leucine-t yrosine COOH (SEQ ID NO:2);
- (2) a peptide having the amino acid sequence NH.sub.2 -cysteine-glycine-serine-glutamic acid-glutamic acid-leucine-arginine-serine-leucine-tyrosine-asparagine-threonine-valine- alanine-threonine-COOH (SEQ ID NO:10);
- (3) a peptide having the amino acid sequence NH.sub.2 -leucine-arginine-proline-glycine-glycine-lysine-lysine-lysine-tyrosine-ly sine-leucine-lysine-histidine-isoleucine-valine -COOH (SEQ ID NO:11);
- (4) a peptide having the amino acid sequence NH.sub.2 -cysteine-leucine-arginine-proline-glycine-glycine-lysine-lysine-lysine-ty rosine-lysine-leucine-lysine-histidine -isoleucine-valine-COOH (SEQ ID NO:4);
- (5) a peptide having the amino acid sequence NH.sub.2 -phenylalanine-arginine-aspartic acid-tyrosine-valine-aspartic acid-arginine-phenylalanine-tyrosine-lysine-threonine -leucine-arginine-alanine-glutamic acid-cysteine-COOH (SEQ ID NO:5);
- (6) a peptide having the amino acid sequence NH.sub.2 -leucine-glutamic acid-glutamic acid-methionine-methionine-threonine-alanine-cysteine-glutamine-glycine-va line-glycine-glycine-proline-glycine-tyrosine-COOH (SEQ ID NO:6);
- (7) a peptide having the amino acid sequence NH.sub.2 -cysteine-valine-glycine -glycine-proline-glycine-histidine-lysine-alanine-arginine-valine-leucine- COOH (SEQ ID NO:7);
- (8) a peptide having the amino acid sequence NH.sub.2 -aspartic acid-leucine -asparagine-threonine-methionine-leucine-asparagine-threonine -valine-glycine-glycine -histidine-glutamine-alanine-alanine-cysteine-COOH (SEQ ID NO:8);
- and
- (9) a peptide having the amino acid sequence NH.sub.2 -valine-histidine-glutamine -alanine-isoleucine-serine-proline-arginine-threonine-leucine-asparagine-a lanine-tryptophan-valine-lysine-cysteine-COOH (SEQ ID NO:9).
10 more elements
A method of assaying a sample of cells for the presence of cytotoxic T lymphocytes, said method comprising:
- (i) incubating said sample of cells with labeled B lymphoblastoid target cells matched for HLA type in the presence of a peptide for a time and under conditions sufficient to result in release of label;
- (ii) determining the amount of label released;
- and
- (iii) correlating the amount of label released with the number of cytotoxic T lymphocytes present in said sample of cells,
- wherein said peptide is selected from the group consisting of:
- (1) a peptide having the amino acid sequence NH.sub.2 -valine-glutamine -asparagine-alanine-asparagine-proline-aspartic acid-cysteine-lysine-threonine-isoleucine -leucine-lysine-alanine-leucine-tyrosine COOH (SEQ ID NO:2);
- (2) a peptide having the amino acid sequence NH.sub.2 -cysteine-glycine-serine -glutamic acid-glutamic acid-leucine-arginine-serine-leucine-tyrosine-asparagine-threonine -valine-alanine-threonine-COOH (SEQ ID NO:10);
- (3) a peptide having the amino acid sequence NH.sub.2 -leucine-arginine-proline -glycine-glycine-lysine-lysine-lysine-tyrosine-lysine-leucine-lysine-histi dine-isoleucine-valine -COOH (SEQ ID NO:11);
- (4) a peptide having the amino acid sequence NH.sub.2 -cysteine-leucine-arginine -proline-glycine-glycine-lysine-lysine-lysine-tyrosine-lysine-leucine-lysi ne-histidine-isoleucine-valine-COOH (SEQ ID NO:4);
- (5) a peptide having the amino acid sequence NH.sub.2 -phenylalanine-arginine -aspartic acid-tyrosine-valine-aspartic acid-arginine-phenylalanine-tyrosine-lysine-threonine -leucine-arginine-alanine-glutamic acid-cysteine-COOH (SEQ ID NO:5);
- (6) a peptide having the amino acid sequence NH.sub.2 -leucine-glutamic acid -glutamic acid-methionine-methionine-threonine-alanine-cysteine-glutamine-glycine-va line -glycine-glycine-proline-glycine-tyrosine-COOH (SEQ ID NO:6);
- (7) a peptide having the amino acid sequence NH.sub.2 -cysteine-valine-glycine -glycine-proline-glycine-histidine-lysine-alanine-arginine-valine-leucine- COOH (SEQ ID NO:7);
- (8) a peptide having the amino acid sequence NH.sub.2 -aspartic acid-leucine -asparagine-threonine-methionine-leucine-asparagine-threonine -valine-glycine-glycine -histidine-glutamine-alanine-alanine-cysteine-COOH (SEQ ID NO:8);
- and
- (9) a peptide having the amino acid sequence NH.sub.2 -valine-histidine-glutamine -alanine-isoleucine-serine-proline-arginine-threonine-leucine-asparagine-a lanine-tryptophan -valine-lysine-cysteine-COOH (SEQ ID NO:9).
12 more elements
Dependencies are inferred from the claim text.